Last reviewed 2026-04-23 · How we verify

IMA901

IMA901 is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.

IMA901 is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations. Used for Metastatic renal cell carcinoma (in combination with sunitinib).

At a glance

Mechanism of action

IMA901 is an autologous dendritic cell vaccine engineered to present patient-specific neoantigens derived from their tumor's unique mutations. The vaccine is designed to stimulate CD8+ T cell responses against these personalized tumor-associated antigens, enabling the immune system to target and eliminate cancer cells. It is typically used in combination with checkpoint inhibitors like sunitinib to enhance anti-tumor immunity.

Approved indications

• Metastatic renal cell carcinoma (in combination with sunitinib)

Common side effects

• Injection site reactions
• Fever
• Fatigue
• Flu-like symptoms

Key clinical trials

• IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma (PHASE3)
• IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• IMA901 CI brief — competitive landscape report
• IMA901 updates RSS · CI watch RSS
• Immatics Biotechnologies GmbH portfolio CI